{
    "doi": "https://doi.org/10.1182/blood.V124.21.198.198",
    "article_title": "Impact of Autologous Transplantation Vs. Chemotherapy Plus Lenalidomide in Newly Diagnosed Myeloma According to Patient Prognosis: Results of a Pooled Analysis of 2 Phase III Trials ",
    "article_date": "December 6, 2014",
    "session_type": "731. Clinical Autologous Transplantation: Results: Clinical Results in Plasma Cell Dyscrasias 2",
    "abstract_text": "Background: Autologous stem cell transplantation (ASCT) improves outcome in comparison with chemotherapy (CC) innewly diagnosed multiple myeloma (NDMM) patients. The primary objective of our analysis was to compare progression-free survival (PFS) and overall survival (OS) of patients randomized to ASCT vs. chemotherapy (CC): we tested the hypothesis that benefit of ASCT could vary in different subsets of patients defined according to baseline prognostic features and response to induction. Methods: Data of 2 phase III multicenter randomized trials (RV-MM-PI-209 and RV-MM-EMN-441) enrolling patients younger than 65 years were pooled together. In both trials, patients received lenalidomide-dexamethasone induction and stem cell mobilization. Patients were randomized to either consolidation with 2 courses of Melphalan 200 mg/mq followed by ASCT (Mel200-ASCT) or 6 cycles of CC plus lenalidomide (CC+R) (RV-MM-PI-209: melphalan-prednisone-lenalidomide; RV-MM-EMN-441: cyclophosphamide-dexamethasone-lenalidomide). We evaluated PFS and OS of Mel200-ASCT vs. CC+R patients in the following subgroups, defined according to baseline features (Karnofsky performance status (PS) [60-70%, 80-100%], International Staging System (ISS) stage [I, II, III], cytogenetic profile [presence of del17 or t(4;14) or t(14;16); absence of del17, t(4;14) and t(14;16)]) and response to induction (\u2265very good partial response [VGPR], <VGPR). Data cut-off was June, 2014. Results: 791 patients were enrolled in the two trials; 529 were eligible for consolidation: 268 patients received Mel200-ASCT and 261 patients received CC+R. Median follow-up for survivors was 4 years. Mel200-ASCT significantly prolonged PFS (median: 42 vs. 24 months, HR 0.52, 95%CI 0.41-0.65, P<0.001) and OS (4-year: 83% vs. 68%, HR 0.59, 95%CI 0.40-0.90 P=0.012) in comparison with CC+R. Mel200-ASCT significantly improved PFS in all the subgroups of patients analyzed. (Table). The most significant OS benefit was noticed in patients with a Karnofsky PS 80-100% (4-year: 85% vs. 73%, HR 0.55, 95% CI 0.35-0.88, P=0.013), with ISS Stage I disease (4-year: OS 89% vs. 77%, HR 0.43, 95% CI 0.20-0.91, P=0.027), with absence of del17, t(4;14) and t(14;16) (4-year: 87% vs. 78%, HR 0.57, 0.33-0.98, P=0.040), and in patients achieving \u2265VGPR after lenalidomide-dexamethasone induction (4-year: 84% vs. 65%, HR 0.46, 95% CI 0.22-0.96, P=0.039). Conclusions: In NDMM patients, Mel200-ASCT significantly improved PFS and OS in comparison with CC+R. The most significant OS advantage was observed in patients with baseline Karnofsky PS 80-100%, ISS Stage I, with absence of del17, t(4;14) or t(14;16) and in patients achieving \u2265VGPR after induction. These data suggest intensifying treatment in good-prognosis patients and in patients with a chemo-sensitive disease. More effective novel agents are needed for patients with a more aggressive disease. Table Subgroup analysis of PFS and OS in Mel200-ASCT vs CC+R patients  . PFS . OS . . HR . 95% CI . P-value . HR . 95% CI . P-value . ISS        Stage I Stage II Stage III  0.43 0.61 0.60 0.30-0.63 0.42-0.90 0.36-0.98 <0.001 0.012 0.042 0.43 0.69 0.75 0.20-0.91 0.33-1.42 0.38-1.47 0.027 0.315 0.397 Cytogenetic profile        No del17, t(4;14), t(14;16) Del17 or t(4;14) or t(14;16)  0.61 0.44 0.44-0.86 0.27-0.70 0.004 <0.001 0.57 0.60 0.33-0.98 0.31-1.15 0.040 0.120 Karnofsky PS        60-70% 80-100%  0.46 0.52 0.26-0.81 0.40-0.68 0.008 <0.001 0.72 0.55 0.29-1.73 0.35-0.88 0.450 0.013 Response to induction        \u2265 VGPR <VGPR  0.48 0.53 0.30-0.80 0.40-0.70 <0.001 <0.001 0.46 0.71 0.22-0.96 0.43-1.18 0.039 0.193 . PFS . OS . . HR . 95% CI . P-value . HR . 95% CI . P-value . ISS        Stage I Stage II Stage III  0.43 0.61 0.60 0.30-0.63 0.42-0.90 0.36-0.98 <0.001 0.012 0.042 0.43 0.69 0.75 0.20-0.91 0.33-1.42 0.38-1.47 0.027 0.315 0.397 Cytogenetic profile        No del17, t(4;14), t(14;16) Del17 or t(4;14) or t(14;16)  0.61 0.44 0.44-0.86 0.27-0.70 0.004 <0.001 0.57 0.60 0.33-0.98 0.31-1.15 0.040 0.120 Karnofsky PS        60-70% 80-100%  0.46 0.52 0.26-0.81 0.40-0.68 0.008 <0.001 0.72 0.55 0.29-1.73 0.35-0.88 0.450 0.013 Response to induction        \u2265 VGPR <VGPR  0.48 0.53 0.30-0.80 0.40-0.70 <0.001 <0.001 0.46 0.71 0.22-0.96 0.43-1.18 0.039 0.193 View Large Disclosures Gay: Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria; Sanofi: Membership on an entity's Board of Directors or advisory committees. Off Label Use: Off-label use of Lenalidomide.. Hajek: Janssen: Honoraria; Celgene: Consultancy, Honoraria; Merck: Consultancy, Honoraria. Di Raimondo: Janssen-Cilag: Honoraria; Celgene: Honoraria. Caravita: Celgene: Honoraria. Patriarca: Merck Sharp & Dohme: Honoraria; Janssen and Cilag: Honoraria; Celgene: Honoraria. Offidani: Janssen-Cilag: Honoraria; Mundipharma: Honoraria; Amgen: Honoraria; Sanofi: Honoraria; Novartis: Honoraria; Celgene: Honoraria. Ria: Janssen-Cilag: Consultancy; Novartis: Consultancy; Italfarmaco: Consultancy; Celgene: Consultancy. Cavallo: Onyx: Honoraria; Janssen-Cilag: Honoraria; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees. Petrucci: Bristol-Myers Squibb: Honoraria; Sanofi: Honoraria; Celgene: Honoraria; Janssen-Cilag: Honoraria. Boccadoro: Janssen-Cilag: Consultancy, Membership on an entity's Board of Directors or advisory committees; Onyx: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sanofi: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees. Spencer: Celgene: Honoraria. Palumbo: Sanofi Aventis: Honoraria; Bristol-Myers Squibb: Consultancy, Honoraria; Array BioPharma: Honoraria; Genmab A/S: Consultancy, Honoraria; Celgene: Consultancy, Honoraria; Janssen-Cilag: Consultancy, Honoraria; Millennium Pharmaceuticals, Inc.: Consultancy, Honoraria; Onyx Pharmaceuticals: Consultancy, Honoraria; Amgen: Consultancy, Honoraria.",
    "topics": [
        "chemotherapy regimen",
        "lenalidomide",
        "multiple myeloma",
        "phase 3 clinical trials",
        "transplantation, autologous",
        "autologous stem cell transplant",
        "chief complaint",
        "dexamethasone",
        "melphalan",
        "off-label use"
    ],
    "author_names": [
        "Francesca Gay, MD",
        "Chiara Cerrato, MD",
        "Roman Hajek",
        "Francesco Di Raimondo, MD",
        "Tommaso Caravita, MD",
        "Antonietta Pia Falcone, MD",
        "Francesca Patriarca, MD",
        "Stefano Pulini",
        "Paola Finsinger, MD",
        "Giovannino Ciccone",
        "Paolo Corradini, MD",
        "Agostina Siniscalchi, MD",
        "Francesca Donato",
        "Dina Ben Yehuda",
        "Massimo Offidani, MD",
        "Jiri Minarik, MD PhD",
        "Roberto Ria, MD",
        "Federica Cavallo, MD",
        "Lucio Catalano, MD",
        "Maide Cavalli, MD",
        "Ludek Pour, Doc, MD PhD",
        "Maria Teresa Petrucci, MD",
        "Izhar Hardan, MD",
        "Mario Boccadoro, MD",
        "Andrew Spencer, MD",
        "Antonio Palumbo, MD"
    ],
    "author_dict_list": [
        {
            "author_name": "Francesca Gay, MD",
            "author_affiliations": [
                "Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Chiara Cerrato, MD",
            "author_affiliations": [
                "Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Roman Hajek",
            "author_affiliations": [
                "Dept. of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Francesco Di Raimondo, MD",
            "author_affiliations": [
                "Italian Multiple Myeloma Network, GIMEMA, Italy "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Tommaso Caravita, MD",
            "author_affiliations": [
                "Italian Multiple Myeloma Network, GIMEMA, Italy "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Antonietta Pia Falcone, MD",
            "author_affiliations": [
                "Italian Multiple Myeloma Network, GIMEMA, Italy "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Francesca Patriarca, MD",
            "author_affiliations": [
                "Italian Multiple Myeloma Network, GIMEMA, Italy "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Stefano Pulini",
            "author_affiliations": [
                "Italian Multiple Myeloma Network, GIMEMA, Italy "
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Paola Finsinger, MD",
            "author_affiliations": [
                "Italian Multiple Myeloma Network, GIMEMA, Italy "
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Giovannino Ciccone",
            "author_affiliations": [
                "Unit of Clinical Epidemiology, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, Torino, Italy "
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Paolo Corradini, MD",
            "author_affiliations": [
                "Italian Multiple Myeloma Network, GIMEMA, Italy "
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Agostina Siniscalchi, MD",
            "author_affiliations": [
                "Italian Multiple Myeloma Network, GIMEMA, Italy "
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Francesca Donato",
            "author_affiliations": [
                "Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy "
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Dina Ben Yehuda",
            "author_affiliations": [
                "Hadassah Medical Center, Jerusalem, Israel "
            ],
            "author_rank": 14,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Massimo Offidani, MD",
            "author_affiliations": [
                "Italian Multiple Myeloma Network, GIMEMA, Italy "
            ],
            "author_rank": 15,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Jiri Minarik, MD PhD",
            "author_affiliations": [
                "University Hospital and Palacky University Olomouc, Olomouc, Czech Republic "
            ],
            "author_rank": 16,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Roberto Ria, MD",
            "author_affiliations": [
                "Italian Multiple Myeloma Network, GIMEMA, Italy "
            ],
            "author_rank": 17,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Federica Cavallo, MD",
            "author_affiliations": [
                "Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy "
            ],
            "author_rank": 18,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Lucio Catalano, MD",
            "author_affiliations": [
                "Italian Multiple Myeloma Network, GIMEMA, Italy "
            ],
            "author_rank": 19,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Maide Cavalli, MD",
            "author_affiliations": [
                "Italian Multiple Myeloma Network, GIMEMA, Italy "
            ],
            "author_rank": 20,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Ludek Pour, Doc, MD PhD",
            "author_affiliations": [
                "University Hospital Brno, Brno, Czech Republic "
            ],
            "author_rank": 21,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Maria Teresa Petrucci, MD",
            "author_affiliations": [
                "Italian Multiple Myeloma Network, GIMEMA, Italy "
            ],
            "author_rank": 22,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Izhar Hardan, MD",
            "author_affiliations": [
                "Hematology Division, Meir Medical Center, Kfar-Saba, Israel "
            ],
            "author_rank": 23,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Mario Boccadoro, MD",
            "author_affiliations": [
                "Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy "
            ],
            "author_rank": 24,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Andrew Spencer, MD",
            "author_affiliations": [
                "Alfred Health-Monash University, Melbourne, Australia "
            ],
            "author_rank": 25,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Antonio Palumbo, MD",
            "author_affiliations": [
                "University of Torino, Torino, Italy"
            ],
            "author_rank": 26,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-29T12:58:29",
    "is_scraped": "1"
}